EvodiaBio Raises €6M To Grow Sustainable Flavour Tech

The round was led by American investment firm RA Capital Management’s Planetary Health Fund and included new investors Wild Radicals and Francis Family Funds.

Existing investors also participated, including EIFO, Ananke Ventures, Newtree Impact, PINC (Paulig), co-founders Jarne Elleholm and Sotirios Kampranis, CEO Camilla Kloss Fenneberg, and board members Flemming Besenbacher, Anne Cabotin, and Andreas Fibig.

“I am proud of our team – within just three and a half years, we have gone from a research project to industrial production with all necessary approvals and a profitable product. That is rarely seen in the BioTech industry. This investment enables us to accelerate global growth and realise our ambition of becoming a leader in industrial BioTech, says Camilla Fenneberg, CEO of EvodiaBio.

In 2025 EU-Startups reported continued investor interest in fermentation-based and sustainable BioTech, providing a strong context for EvodiaBio’s recent funding round.

Read Full Article - Nodu Raises $1.45M To Expand Stablecoin Payment Infrastructure

French startup Fungu’it raised €4 million to develop natural flavorings through fungi fermentation highlighting growing demand for alternative aromas and tastes with a lower environmental footprint. In a related area Swedish precision-fermentation company Melt&Marble secured €7.3 million to scale its designer fats for food and beauty applications while German startup Kynda raised €3 million to expand sustainable fungal protein production.

Together, these 2025 rounds represent roughly €14.3 million invested across flavor, ingredient and fermentation-driven BioTech in Europe.

Within this landscape EvodiaBio’s €6 million raise positions the company at the heart of a broader data-supported trend: capital flowing into industrial BioTech platforms that leverage fermentation in food and beverage value chains. Its focus on yeast-derived natural aromas complements adjacent developments in flavors, fats, and proteins, underlining the growing investor appetite for sustainable, fermentation-based solutions.

“RA Capital’s investment in EvodiaBio at this stage underscores the company’s strong position. It confirms that we have removed the key risks related to technology, production and commercialisation. We have proven that the technology works, that customers are interested in the product, and that the business model has been profitable from day one. Now we are ready to accelerate growth, says Jarne Elleholm, Chairman of the Board at EvodiaBio.

He adds:”What EvodiaBio has achieved in record time is highly unusual in our industry. Moving from the laboratory to a complete production platform, global partnerships, and market interest in such a short time demonstrates that Denmark has the potential to become a leading hub for biosolutions. The new capital allows us to accelerate even further and show how far industrial BioTech can take Denmark.”

Founded in 2021 EvodiaBio is an industrial BioTech company specializing in sustainable aromas produced through fermentation. Its technology is commercially applied in the beverage industry, enabling the creation of natural aromas with significantly lower resource use and CO₂ emissions compared to traditional methods.

In just over three years, EvodiaBio has progressed from laboratory research to industrial-scale production of yeast-derived natural monoterpenes.

Since launching its Yops technology platform earlier this year, the company has gained global commercial traction, with more than 70 commercial brews and over 10 projects with top-40 breweries worldwide.

“EvodiaBio’s technology platform convincingly solves the problem of efficiently and sustainably producing natural aromas at industrial scale. The team has executed with a speed and capital efficiency rarely seen in BioTech,” says Kyle Teamey, Managing Partner at RA Capital.

Teamey adds: “We see great potential in the company’s channel partnerships with Symrise and Lallemand and we are excited to support the company as it scales internationally and expands into new segments.”

With its latest investment and strong partnerships, EvodiaBio is well positioned to accelerate growth. The company plans to expand into new markets, including Asia, and apply its sustainable fermentation technology across additional industries, such as other beverages, wine, and the broader aroma sector.

This latest funding round marks EvodiaBio’s third in three years bringing its total capital raised to €20 million (DKK 150 million).

“This investment places us in a strong position to accelerate our growth and expand our technology into new markets, especially in Asia. We have achieved strong commercial validation, but we are still early in our growth journey. Our goal is to become a global leader in industrial biotech, and we see a tremendous opportunity to enter multiple industries with our sustainable and efficient solutions,” adds Fenneberg.